Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 2/20 | 0.61 |
| ▸ | KDR | P35968 | 2/20 | 0.61 |
| ▸ | LPL | P06858 | 1/20 | 0.56 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 5/20 | 0.53 |
| ▸ | CA2 | P00918 | 5/20 | 0.53 |
| ▸ | CA9 | Q16790 | 5/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | CDK9 | P50750 | 1/20 | 0.53 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2730940 | 0.88 | CA1 (0.53) | PDGFRBKDRLPLLIPGCA1 | |
| SCHEMBL5675377 | 0.87 | PDGFRB (0.58) | PDGFRBKDRLPLLIPGCA1 | |
| SCHEMBL422455 | 0.86 | LPL (0.61) | PDGFRBKDRLPLLIPGCA1 | |
| SCHEMBL441557 | 0.86 | RAB9A (0.62) | PDGFRBKDRSMN1; SMN2TP53TSHR | |
| SCHEMBL5675802 | 0.86 | NPC1 (0.62) | PDGFRBKDRLPLLIPGCA1 | |
| SCHEMBL423956 | 0.86 | PDGFRB (0.58) | PDGFRBKDRCA1CA2CA9 | |
| SCHEMBL441291 | 0.86 | CA1 (0.55) | PDGFRBKDRLIPGCA1CA2 | |
| SCHEMBL29517828 | 0.86 | RAB9A (0.62) | PDGFRBKDRSMN1; SMN2TP53TSHR | |
| SCHEMBL441861 | 0.86 | CA1 (0.54) | PDGFRBKDRLPLLIPGCA1 | |
| SCHEMBL706622 | 0.85 | CA1 (0.57) | PDGFRBKDRLPLLIPGCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3481831-B1 | 4-AMINOPYRAZOLO[3,4-D]PYRIMIDINYLAZABICYCLO DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO LTD (KR) | 2023-09-06 | — | — | EP | disclosed |
| EP-3481831-B1 | 4-AMINOPYRAZOLO[3,4-D]PYRIMIDINYLAZABICYCLO DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO LTD (KR) | 2023-09-06 | — | — | EP | disclosed |
| CN-109153680-B | 4-aminopyrazolo [3,4-d ] pyrimidinylazabicyclo derivatives and pharmaceutical compositions containing the same | 株式会社大熊制药 | 2021-04-23 | — | — | CN | disclosed |
| US-20200031811-A1 | SUBSTITUTED MONO- AND POLYAZANAPHTHALENE DERIVATIVES AND THEIR USE | BASILEA PHARM INT AG (CH) | 2020-01-30 | — | — | US | disclosed |
| US-20200031811-A1 | SUBSTITUTED MONO- AND POLYAZANAPHTHALENE DERIVATIVES AND THEIR USE | BASILEA PHARM INT AG (CH) | 2020-01-30 | — | — | US | disclosed |
| US-10399988-B2 | 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo derivatives and pharmaceutical composition comprising the same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2019-09-03 | — | — | US | disclosed |
| US-10399988-B2 | 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo derivatives and pharmaceutical composition comprising the same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2019-09-03 | — | — | US | disclosed |
| US-20190161488-A1 | Novel 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo Derivatives and Pharmaceutical Composition Comprising the Same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2019-05-30 | — | — | US | disclosed |
| US-20190161488-A1 | Novel 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo Derivatives and Pharmaceutical Composition Comprising the Same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2019-05-30 | — | — | US | disclosed |
| US-20180002321-A1 | SUBSTITUTED MONO- AND POLYAZANAPHTHALENE DERIVATIVES AND THEIR USE | Basilea Pharmaceutica International AG (CH) | 2018-01-04 | — | — | US | disclosed |
| US-20060252782-A1 | Sulfoximine-macrocycle compounds and salts thereof, pharmaceutical compositions comprising said compounds, methods of preparing same and uses of same | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-11-09 | — | — | US | disclosed |
| EP-1710246-A1 | Sulfoximine-pyrimidine Macrocycles and the salts thereof, a process for making them, and their pharmaceutical use against cancer | Schering Aktiengesellschaft (DE) | 2006-10-11 | — | — | EP | disclosed |
| US-20060194823-A1 | Sulfonamido-macrocycles as Tie2 inhibitors and the salts thereof, a pharmaceutical composition comprising these compounds, the method of preparing and the use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-08-31 | — | — | US | disclosed |
| WO-2006077319-A1 | SUBSTITUTED PYRAZOLO-PYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | AVENTIS PHARMA S.A. (FR) | 2006-07-27 | — | — | WO | disclosed |
| EP-1674469-A1 | Sulfonamido-macrocycles as Tie2 inhibitors | Schering Aktiengesellschaft (DE) | 2006-06-28 | — | — | EP | disclosed |
| US-20060074102-A1 | Kinase inhibitors as therapeutic agents | ABBOTT LABORATORIES | 2006-04-06 | — | — | US | disclosed |
| EP-1638941-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2006-03-29 | — | — | EP | disclosed |
| WO-2005110410-A2 | KINASE INHIBITORS AS THERAPEUTIC AGENTS | ABBOTT LABORATORIES (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050020603-A1 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBVIE INC. | 2005-01-27 | — | — | US | disclosed |
| WO-2004113304-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10399988-B2 | 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo derivatives and pharmaceutical composition comprising the same | ITK, BTK, TYK2 | PDGFRB 645/4885KDR 1438/4885LPL 3509/4885 |
| US-20060194823-A1 | Sulfonamido-macrocycles as Tie2 inhibitors and the salts thereof, a pharmaceutical composition comprising these compounds, the method of preparing and the use thereof | TEK, TIE1, KDR | PDGFRB 15/4885KDR 3/4885LPL 3614/4885 |
| US-20060074102-A1 | Kinase inhibitors as therapeutic agents | ABL1, MAP3K19, MAP3K20 | PDGFRB 444/4885KDR 402/4885LPL 3783/4885 |
| US-20050020603-A1 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABL1, BLK, BTK | PDGFRB 549/4885KDR 724/4885LPL 4298/4885 |
| US-20190161488-A1 | Novel 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo Derivatives and Pharmaceutical Composition Comprising the Same | BTK, ITK, TYK2 | PDGFRB 738/4885KDR 1410/4885LPL 3509/4885 |
| US-20180002321-A1 | SUBSTITUTED MONO- AND POLYAZANAPHTHALENE DERIVATIVES AND THEIR USE | CBR3, SCO2, CBR1 | PDGFRB 2582/4885KDR 1870/4885LPL 3921/4885 |
| US-20060252782-A1 | Sulfoximine-macrocycle compounds and salts thereof, pharmaceutical compositions comprising said compounds, methods of preparing same and uses of same | TEK, FLT1, TIE1 | PDGFRB 46/4885KDR 4/4885LPL 4386/4885 |
| US-20200031811-A1 | SUBSTITUTED MONO- AND POLYAZANAPHTHALENE DERIVATIVES AND THEIR USE | CBR3, SCO2, CBR1 | PDGFRB 2589/4885KDR 1852/4885LPL 3925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.